This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



vorapaxar (Zontivity®)


Reference No. 1034

Publication date:
20/05/2015


Appraisal information

vorapaxar (Zontivity®) 2 mg film-coated tablet


Company: Merck Sharp & Dohme Ltd
BNF category: Cardiovascular system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 15/05/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, vorapaxar (Zontivity®) cannot be endorsed for use within NHS Wales co-administered with acetylsalicylic acid and, where appropriate, clopidogrel, for the reduction of atherothrombotic events in adult patients with a history of myocardial infarction (MI); or symptomatic peripheral arterial disease (PAD). This product is currently not marketed in the UK.
Statement of Advice (SOA)
Download